Trimebutine

	WikiDoc Resources for Trimebutine
Articles
Most recent articles on Trimebutine Most cited articles on Trimebutine Review articles on Trimebutine Articles on Trimebutine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Trimebutine Images of Trimebutine Photos of Trimebutine Podcasts & MP3s on Trimebutine Videos on Trimebutine
Evidence Based Medicine
Cochrane Collaboration on Trimebutine Bandolier on Trimebutine TRIP on Trimebutine
Clinical Trials
Ongoing Trials on Trimebutine at Clinical Trials.gov Trial results on Trimebutine Clinical Trials on Trimebutine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Trimebutine NICE Guidance on Trimebutine NHS PRODIGY Guidance FDA on Trimebutine CDC on Trimebutine
Books
Books on Trimebutine
News
Trimebutine in the news Be alerted to news on Trimebutine News trends on Trimebutine
Commentary
Blogs on Trimebutine
Definitions
Definitions of Trimebutine
Patient Resources / Community
Patient resources on Trimebutine Discussion groups on Trimebutine Patient Handouts on Trimebutine Directions to Hospitals Treating Trimebutine Risk calculators and risk factors for Trimebutine
Healthcare Provider Resources
Symptoms of Trimebutine Causes & Risk Factors for Trimebutine Diagnostic studies for Trimebutine Treatment of Trimebutine
Continuing Medical Education (CME)
CME Programs on Trimebutine
International
Trimebutine en Espanol Trimebutine en Francais
Business
Trimebutine in the Marketplace Patents on Trimebutine
Experimental / Informatics
List of terms related to Trimebutine

Trimebutine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	A03AA05 (WHO) ;
Identifiers
	IUPAC name 2-(Dimethylamino)-2-phenylbutyl 3,4,5-trimethoxybenzoate;
CAS Number	39133-31-8 ;
PubChem CID	5573;
ChemSpider	5372 ;
UNII	QZ1OJ92E5R;
ChEMBL	ChEMBL190044 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C22H29NO5
Molar mass	387.47 g/mol
3D model (JSmol)	Interactive image;
	SMILES CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C;
	InChI InChI=1S/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3 ; Key:LORDFXWUHHSAQU-UHFFFAOYSA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.^[1] The maleic acid salt of trimebutine is marketed under the trademark of Debridat, Recutin, Polybutin,^[2] or Modulon for treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug metabolism of trimebutine in human beings is nortrimebutine,^[3] which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract.^[4] Both Trimebutine and its metabolite are commercially available.

References

↑ Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. Journal of Pharmacobiodynamics. 1990 Jul;13(7):448-53. PMID 1963196
↑ Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC–MS/MS method. Clinica Chimica Acta. 2007 Jan;375(1-2):69-75. PMID 16854404
↑ F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. The Journal of Pharmacology and Experimental Therapeutics 1999;289:1391–1397. PMID 10336531
↑ Hiyama, T.; Yoshihara, M.; Tanaka, S.; Haruma, K.; Chayama, K. (Apr 2009). "Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract" (PDF). J Gastroenterol Hepatol. 24 (4): 537–46. doi:10.1111/j.1440-1746.2009.05780.x. PMID 19220673.

Template:Drugs for functional gastrointestinal disorders}

[1] Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. Journal of Pharmacobiodynamics. 1990 Jul;13(7):448-53. PMID 1963196

[2] Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC–MS/MS method. Clinica Chimica Acta. 2007 Jan;375(1-2):69-75. PMID 16854404

[3] F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. The Journal of Pharmacology and Experimental Therapeutics 1999;289:1391–1397. PMID 10336531

[Hiyama-2009-4] Hiyama, T.; Yoshihara, M.; Tanaka, S.; Haruma, K.; Chayama, K. (Apr 2009). "Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract" (PDF). J Gastroenterol Hepatol. 24 (4): 537–46. doi:10.1111/j.1440-1746.2009.05780.x. PMID 19220673.

[1]

[2]

[3]

[4]

Trimebutine

Overview

See also

References

Navigation menu

Trimebutine

Overview

See also

References

Navigation menu

Search